Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Generics could undercut that price to drive Amarin out of the market. Insurers will always go with the lowest price generic and Amarin trying to win a price war with Teva, Hikma etc will end badly for Amarin.
While I agree with your comments regarding national security, the fact that producing and selling generics is a business with slim margins and extremely competitive is the point. My post is in regard to Amarin's ability to compete in that market and make a profit against much larger companies. Established generic manufacturers will simply undercut Amarin and put them out of business.
Amarin's future, to the extent it has one, is in Europe and ROW. The U.S. market is dead.
Why turning Amarin into a generic to sell vascepa won't work. The article is about Kodak but the relevant info regarding generic production is the meat of the article.
https://www.google.com/amp/s/investorplace.com/2020/09/kodk-stock-is-going-to-0/amp/
Well, just one more nail in the coffin.
That's the article I read.
Apparently statins are effective in helping prevent covid infections according to an article I just read.
Viruses mutate. This comes under the sun rises in the east category. Does the article say anything about the potency of the mutations.
I'm pretty sure funds are unwinding their positions here. No telling where we stand in that process except to say it's only going to get worse.
AH volume was only 75000 shares. It's nothing.
I think funds are getting out without crashing the share price any more than necessary. The selloff could continue for sometime. Still no word on the LoOI from the EU yet. This is like the sloop john b. Worst trip I've ever been on.
I phrased it that way to get an answer to the question of why the deadline passed and no response. The question has been asked here several times by different posters but the board is focused on the appeal to such an extent that no other issues get addressed. And frankly, Europe is far more important now than a less than 1 percent shot of getting an en banc hearing.
By the way, where is Raf and HDG?
With no news from Europe I'm assuming the worst. Amarin has been turned down and the company hasn't revealed it yet.
Any news from the EU? Just asking since we were supposed to have a reply last week.
It will be lower than that by end of day.
Any news on the EU regarding the LoOI which was due last week? This question has been asked numerous times but no answers.
Up 7%, 4 cents, on the European exchange. Not spectacular but up is good.
The board has an idée fixe at the moment. Multitasking isn't possible. It's kind of amusing examining the psychology of it. They're plotting Custer's last stand while ignoring a relevant issue.
Not an issue? The board doesn't seem to think it's a big deal. The market either as the share price hasn't changed. Anyway, I thought yesterday was the deadline for the EU response.
It may apply to Amarin in more ways than one. Adam Fuerstein is mentioned prominently in that article. I expect him to trash NWBO after the results are released. If the stock spikes he will work to drive it back down. Hopefully NWBO mgt look for a quick sale to BP soon after the data is made public. Assuming it's good news of course.
C'mon man!
So much negativity on the board. I love it. Everyone was so positive we were going to be bought/win the court case/win the appeal and now everyone's pissed. Which means, given the track record here, we're about to kick ass. Oorah!
He might be thinking of Pinochet.
What is the point of this trial? Will it get our patents back? Will it forestall generic entry? What's the point?
If they get a good top line readout I think it's a 5 to 10 dollar stock and a buyout candidate. That's about it and I'm invested there. No blue sky dreams.
From an investors perspective there is no benefit. It would likely harm shareholders and any benefit would be in the future assuming it was even successful.
The benefit would be to JT's ego.
Has anyone considered the possibility Amarin might seek to buy a company? This is just an entertaining thought on my part but it hasn't been addressed here so I'm throwing it out there for comment. A small biotech with a drug in the pipeline that has promise but needs funding to complete the necessary study. A company with a strong r&d department but not much in the way of marketing know-how. Purchase financed with stock.
The small Canadian study started in June and due to end in December should be about halfway through the 100 patient enrollment process by now and should be producing tangible results, good or bad. The course of treatment was quick so analysis of results for each patient shouldn't take long. IIRC this isn't a blinded study but I could be wrong.
China trial is for the marine label but info posted here long ago indicates they will apply the reduce it label when they approve it.
ILT. What is your opinion of this. From nwbo yahoo board.
They are out of money.
They have no more shares to give away at $0.14 without coming back to shareholders to ask them to approve more, and we all know that's not going to happen. They've played this out as long as they could, but now they are out of options for raising any significant new funds. They can't pay themselves anymore. So that is why they could have finally thrown in the towel and decided to release the failed results. Think about it.
By saying, "we think this study is going to be a major contribution to the field in terms of data," the CEO wasn't exactly brimming with confidence about the product that data is attached to. Yes, she followed that with a tepid statement saying she "hopes" they get approval, but she's been saying that for over 13 years. They know what's coming, and they've known it for the last five years.
On another note, has anyone here investigated whether there is any kind of personal relationship between anyone at NWBO and the two principals at Flaskworks? I'd be interested to know whether this was actually a research-based acquisition, or if it was just another in their long list of buddy-buddy shenanigans. We know how they love to make their buddies rich whenever possible. Wouldn't surprise me if there is more to the Flaskworks story than we know.''
There is a book called From the Jaws of Victory that analyzes great battles in history that were for all practical purposes were already won but decisions by inept leadership forfeited victory. An entertaining read and apropos here I think.
Well, I guess Germany is the best place to start if you're going it alone. I believe first year drug prices will equal US prices for one year.
NWBO went up on heavy volume in the last few minutes of trading. Apparently insiders exercised options per the yahoo message board. They are due to release top line results from their stage 3 trial by the end of the month.
Thanks for that. Very informative.
I note that Adam Fuerstein is mentioned prominently in that article. Singled out in fact. He's painted as the snake that he is.
What is the status of the 500mg case? Was it consolidated? Still pending? Irrelevant now?
That article mentions opportunities in the middle East but there was a poster here some time back that said vascepa was not available in the countries it's already approved for leading me to question whether there's any value there at all.
I guess I should have said implements go it alone. I don't think the market takes him seriously now.
We'll be in the 2's if JT announces gia in Europe as I suspect he will.
New 52 week low incoming?
Don't they have to do that as part of the process to get an anda? If so, they've already accomplished that.